AmyriAD leaves no leaf unturned with upcoming Phase III Alzheimer’s trials
The company aims to drive a small molecule resurgence with its lead Alzheimer’s symptom relief agent AD-101.
The company aims to drive a small molecule resurgence with its lead Alzheimer’s symptom relief agent AD-101.